



14th Asian Congress of Pediatric Nephrology

Evidence-based clinical management in pediatric nephrology, An IPNA Scientific Workshop March 30-31, 2021 Taipei, Taiwan.

Evidence-based clinical management in pediatric nephrology is a challenging and major goal of our Society. Indeed, most diseases pediatric nephrologists deal with are severe rare diseases requiring optimal management in the face of a limited number of randomized clinical trials.

To this end, IPNA has successfully begun a new initiative with the aim of developing "IPNA Clinical Optimal Recommendations (IPNA-CPR)", addressing important global topics in the field of pediatric nephrology. The first IPNA-CPR on steroid resistant nephrotic syndrome (SRNS) will soon be published in Pediatric Nephrology the journal of the IPNA.

To address this, the Best Practice and Standards Committee is organizing a scientific workshop solely dedicated to guideline methodology, distribution and implementation. More than 20 new guidelines will be presented by international experts. The scientific workshop precedes the 14th Asian Congress of Pediatric Nephrology (ACPN) and will be held over 1 1/2-days with symposia, invited lectures, free oral presentations, panel discussions, and guided poster walks. Since the workshop follows directly the junior master class (March 29-30) one can smoothly attend all three events.

@Taipei Grand Hotel 10F Grand Ballroom

2021. March 30-31

Important Dates for Registration

January 10, 2021

Deadline for Early Bird Registration

February 28, 2021

Deadline for Standard Registration

Important Dates for Abstract Submission

July 01, 2020 November 01, 2020 November 24, 2020 January 31, 2021 Online System Opens for Abstract Submission & Travel Grants

Deadline for Abstract Submission & Travel Grants Application

Notification of Abstract Acceptance & Travel Grants

Deadline for Abstract Author Registration

More information: www.acpn2020.com





Taipei Grand Hotel Muslim Friendly Restaurant (MFR) Muslim Friendly Tourism (MFT)

Day 1 March 30 (Tue.)		
08:30-08:40	Welcome	
08:40-09:10	Global needs for guidelines -Perspectives from low, middle and high-income countries; rare and common conditions: An IPNA survey (Olivia Boyer, France; Khalid Al-Hasan, KSA; Pankaj Hari, India)	
09:10-10:00	Methodology I -Interpreting clinical trial results – confidence and magnitude versus P values (Jonathan Craig, Australia) -The appraisal and synthesis of evidence for guideline development (David Tunnicliffe, Australia)	
10:00-10:30	Coffee break	
10:30-12:10	Joined session with IPNA-AsPNA Junior Master Class: Guidelines I: CKD and Transplantation -Guidelines in the management of CKD-MBD in children: learning from KDIGO, NICE and ESPN (Rukshana Shroff, UK) -Clinical practice recommendations for treatment with active vitamin D analogues in children with CKD stages 2-5 and on dialysis - Position paper on the use of cinacalcet in children on dialysis: ESPN (Justine Bacchetta, France) -Clinical practice recommendations for growth hormone treatment in children with CKD: ESPN (Jens Drube, Germany) -Recurrent disease after renal transplantation: ESPN, CERTAIN, ERKNet (Lars Pape, Germany)	
12:10-12:35	Methodology II -Patient's perspective & patient centered outcome measures: SONG initiative (Allison Tong, Australia)	
12:35-13:40	Lunch and Posters	
13:40-15:20	Guidelines II Nephrotic syndrome / HUS -Management of Nephrotic Syndrome in Children: Recommendations from KDIGO (Keisha Gibson, US) -IPNA Clinical Practice Recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome (Agnes Trautmann, Germany) -Congenital Nephrotic Syndrome: ERKNet/ESPN consensus recommendation (Olivia Boyer, France) -Clinical practice recommendations on the diagnosis and management of atypical HUS: HUSi (Christoph Licht, Canada)	
15:20-15:50	Coffee break	
15:50-17:30	Guidelines III Hypertension / CAKUT -Hypertension: The US/AAP and EU/ESH guidelines (Don Batisky, US) -UTI: The North American recommendations (Brian Becknell, US) -UTI and VUR: The Indian recommendations (Pankaj Hari, India) -Obstructive uropathy and renal dysplasia: ERKNet/ESPN consensus (Giovanni Montini, Italy)	
	台:灣 Taiwan	

Day 2 March 31 (Wed.)	
08:30-09:45	Lessons from screening programs & recent clinical trials -Screening programs (II-Soo Ha, Korea) -Clinical trials in IgA nephropathy & vasculitis (Koichi Nakanishi, Japan) -Clinical trials in nephrotic syndrome (Arvind Bagga, India)
09:45-11:00	Guidelines IV Tubulopathies -Clinical practice recommendations for the diagnosis and management of X-linked hypophosphatemia: European societies & rare diseases networks (Francesco Emma, Italy) -Bartter Syndrome: Consensus/Position Paper from the ERKNet expert group for tubular disorders (Karl Peter Schlingmann, Germany) -Distal renal tubular acidosis: Consensus/Position Paper from ESPN and ERKNet (Detlef Böckenhauer, UK)
11:00-11:30	Coffee break
11:30-12:20	Implementation: -Experience from SCOPE (Alicia Neu, US) -Contribution from registries (Franz Schaefer, Germany)
12:20-13:00	Panel discussion: Future directions, challenges (selected speakers of day 1 and 2)
13:00-	Farewell & Lunch

Contact: Prof. Dr. Dieter Haffner, Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Email: Haffner.Dieter@mh-hannover.de

Scientific committee: Dieter Haffner (chair), Khalid AlHasan, Ali Duzova, Olivia Boyer, Xu Hong, Montini Giovanni, Koichi Nakanishi, Il-Soo Ha, Arvind Bagga, Melvin Bonilla, Pankaj Hari

